Merck Canada

MERCK MAKING NEWS

Corporate News

November 26, 2021
Kingston Health Sciences Centre Expands Lung Diagnostic Assessment Program to Napanee, ON

November 23, 2021
Health Canada Approves KEYTRUDA^® (pembrolizumab) in Combination with Chemotherapy for the Treatment of Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)

November 8 2021
Merck Canada and Guy Lafleur Team Up Against Lung Cancer

September 1, 2021
Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection

August 13, 2021
Merck Canada Files Rolling Submission for Health Canada Approval of Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19

May 10, 2021
Merck Canada Announces Start of Enrollment for Phase 3 Clinical Trial of Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19

April 28, 2021
Merck Canada and MaRS Announce Winners of the Lung Cancer Innovation Challenge

November 19, 2018
Merck Canada reaffirms its commitment to CQDM with a $3.5M contribution to sustain innovation in life sciences

This website is designed to provide members of the media with quick and easy access to recent information about Merck. For additional information, please visit 'About Merck'.

Media Centre

For journalists with a media inquiry, please contact us: 1-833-90MERCK (1-833-906-3725).

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.